Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
PLSH · OTC · United States · Medicinal Chemicals & Botanical Products
In shortPANACEA LIFE SCIENCES HOLDINGS, INC. is loss-making, burns cash and holds more cash than debt, with revenue growing (+46.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -232.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -336.1% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.24× | 0/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | 0/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -3.56× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -13.95 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -66.7% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 4 | 17/100 |
| Revenue growth volatility | 1264.0% | 0/100 |
| Operating margin volatility | 1281.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -35.8% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2023 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 |
|---|---|---|---|---|---|
| Revenue | 0.3 | 9 | 2.1 | 1.6 | 2.4 |
| Cost of revenue | 1.9 | 7 | 1.5 | 1.2 | 1.3 |
| Gross profit | (1.7) | 2 | 0.5 | 0.4 | 1.1 |
| Research & development | 0 | 0 | – | – | – |
| Operating income | (11) | (5.3) | (5.9) | (5.7) | (5.5) |
| Interest expense | 0.5 | 1.5 | 1.1 | 2 | 1.6 |
| Pre-tax income | (10) | (5.2) | (4.8) | (9.1) | (8) |
| Net income | (10) | (5.2) | (4.8) | (9.1) | (8) |
| Diluted EPS | −$0.30 | −$0.31 | −$0.27 | −$0.62 | −$0.48 |
| Diluted shares (millions) | 34 | 17 | 18 | 15 | 17 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of PANACEA LIFE SCIENCES HOLDINGS, INC. are included in the Investor plan. Try free for 7 days →
−13.95 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Mar 31, 2024 · Data updated May 6, 2024